-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $46

Benzinga·12/01/2025 13:51:12
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $39 to $46.